BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12, 2024 16:56 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
August 09, 2024 16:20 ET
|
Edesa Biotech, Inc.
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
June 24, 2024 08:02 ET
|
InflaRx N.V.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Ebenbuild erhält öffentliche Förderung im Rahmen des UBIC-Konsortiums für das Projekt "Digital Lung Twin“
November 28, 2023 04:00 ET
|
AKAMPION
Bundesministerium für Bildung und Forschung (BMBF) bewilligt Fördermittel in Höhe von bis zu 1,8 Millionen Euro München, Deutschland, 28. November 2023 -- Ebenbuild, ein Unternehmen, das...
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
November 28, 2023 04:00 ET
|
AKAMPION
Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF Munich, Germany, November 28, 2023 -- Ebenbuild, a company developing personalized, AI-driven...
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET
|
BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
Acute Respiratory Distress Syndrome Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Leading Companies to Watch Out - MediciNova, Mesoblast, Veru, Pluristem, Avalo, Boehringer Ingelheim, Genentech, Windtree
September 13, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Leading Companies to Watch Out - MediciNova,...
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
September 11, 2023 11:32 ET
|
CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
May 31, 2023 08:00 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3...